EGFR and medulloblastoma: Few tissue biomarkers can predict prognosis in only subsets of specific tumor histotypes: IDH1 in diffuse gliomas, 1p19q co-deletion in anaplastic oligodendrogliomas, MGMT methylation in glioblastomas, MYC family members amplification in medulloblastoma, K1AA1549-BRAF fusion gene in pilocytic astrocytomas, EGFR mutation in medulloblastomas and metastasis, etc. [2–6].